---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-350537"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-08-14T12:10:17+00:00"
generated_at: "2026-08-14T12:15:10.623666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q2: mipletamig 81% remission in AML; Niowave 50/50 radiopharma deal

## Summary
- Cash $9.8M at June 30, 2026; raised $0.6M under Yorkville SEPAs in Q2.
- Mipletamig: 87% clinical benefit rate, 81% remission rate in 31 frontline AML patients; 55% MRD neg, 36% TP53, 6 bridged to transplant.
- Appointed Mary J. Janatpour, Ph.D. as SVP and Chief Scientific Officer.
- Secured $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling work; candidate selection by year-end 2026.
- Entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave took 7.9% equity stake (up to 19.99%).

## SEC filing metadata
- accession: 0001193125-26-350537
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-08-14T12:10:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/0001193125-26-350537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-350537
- JSON: https://secwatch.observer/filing/0001193125-26-350537.json
- Plain text: https://secwatch.observer/filing/0001193125-26-350537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.